Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

241 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study.
Vali Y, Lee J, Boursier J, Petta S, Wonders K, Tiniakos D, Bedossa P, Geier A, Francque S, Allison M, Papatheodoridis G, Cortez-Pinto H, Pais R, Dufour JF, Leeming DJ, Harrison SA, Chen Y, Cobbold JF, Pavlides M, Holleboom AG, Yki-Jarvinen H, Crespo J, Karsdal M, Ostroff R, Zafarmand MH, Torstenson R, Duffin K, Yunis C, Brass C, Ekstedt M, Aithal GP, Schattenberg JM, Bugianesi E, Romero-Gomez M, Ratziu V, Anstee QM, Bossuyt PM; Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS) consortium investigators. Vali Y, et al. Among authors: francque s. Lancet Gastroenterol Hepatol. 2023 Aug;8(8):714-725. doi: 10.1016/S2468-1253(23)00017-1. Epub 2023 Mar 21. Lancet Gastroenterol Hepatol. 2023. PMID: 36958367 Free article.
Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitis.
Ratziu V, Bedossa P, Francque SM, Larrey D, Aithal GP, Serfaty L, Voiculescu M, Preotescu L, Nevens F, De Lédinghen V, Kirchner GI, Trunecka P, Ryder SD, Day CP, Takeda J, Traudtner K. Ratziu V, et al. Clin Gastroenterol Hepatol. 2014 Oct;12(10):1724-30.e5. doi: 10.1016/j.cgh.2014.01.040. Epub 2014 Feb 12. Clin Gastroenterol Hepatol. 2014. PMID: 24530600 Clinical Trial.
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.
Francque SM, Bedossa P, Ratziu V, Anstee QM, Bugianesi E, Sanyal AJ, Loomba R, Harrison SA, Balabanska R, Mateva L, Lanthier N, Alkhouri N, Moreno C, Schattenberg JM, Stefanova-Petrova D, Vonghia L, Rouzier R, Guillaume M, Hodge A, Romero-Gómez M, Huot-Marchand P, Baudin M, Richard MP, Abitbol JL, Broqua P, Junien JL, Abdelmalek MF; NATIVE Study Group. Francque SM, et al. N Engl J Med. 2021 Oct 21;385(17):1547-1558. doi: 10.1056/NEJMoa2036205. N Engl J Med. 2021. PMID: 34670042 Clinical Trial.
Advancing the global public health agenda for NAFLD: a consensus statement.
Lazarus JV, Mark HE, Anstee QM, Arab JP, Batterham RL, Castera L, Cortez-Pinto H, Crespo J, Cusi K, Dirac MA, Francque S, George J, Hagström H, Huang TT, Ismail MH, Kautz A, Sarin SK, Loomba R, Miller V, Newsome PN, Ninburg M, Ocama P, Ratziu V, Rinella M, Romero D, Romero-Gómez M, Schattenberg JM, Tsochatzis EA, Valenti L, Wong VW, Yilmaz Y, Younossi ZM, Zelber-Sagi S; NAFLD Consensus Consortium. Lazarus JV, et al. Among authors: francque s. Nat Rev Gastroenterol Hepatol. 2022 Jan;19(1):60-78. doi: 10.1038/s41575-021-00523-4. Epub 2021 Oct 27. Nat Rev Gastroenterol Hepatol. 2022. PMID: 34707258 Free article. Review.
Nonalcoholic Fatty Liver Disease. Reply.
Francque SM, Bedossa P, Abdelmalek MF. Francque SM, et al. N Engl J Med. 2022 Jan 20;386(3):295-296. doi: 10.1056/NEJMc2118255. N Engl J Med. 2022. PMID: 35045238 No abstract available.
241 results